Relapses of Immune Thrombocytopenia after the Second and Booster Doses of BNT162b2 Vaccine

0Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present here a 65-year-old male patient known for immune thrombocytopenic purpura (ITP) and fluctuating platelet count who experienced a severe exacerbation of thrombocytopenia following BNT162b2 COVID-19 vaccination. One month after the second dose, he presented petechiae and asthenia with isolated thrombocytopenia (platelet count: 3 × 109/L). He recovered after a 4-day course of intravenous corticosteroid treatment and intravenous immunoglobulin therapy. Eight months later, his platelet count was within the normal range, and he received a booster dose of vaccine after premedication with prednisone. Eight days later, his platelet count dropped to 29 × 109/L, but he remained asymptomatic. He received a rescue treatment with prednisone followed by rituximab over 4 weeks, allowing progressive improvement. Our case suggests a strong association between COVID-19 vaccination and the exacerbation of ITP.

Cite

CITATION STYLE

APA

Ratajczak-Enselme, M., Mutoni, G. C., Desmeules, J., Favet, L., & Ing Lorenzini, K. (2023). Relapses of Immune Thrombocytopenia after the Second and Booster Doses of BNT162b2 Vaccine. Acta Haematologica, 146(1), 52–57. https://doi.org/10.1159/000527431

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free